Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)
Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)
批准号:
7930505
负责人:
PAULA M. FRACASSO
金额:
$9.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AbraxaneAcademic Medical CentersAfrican AmericanAlbumin-Stabilized Nanoparticle PaclitaxelAlbuminsAmericanAnnual ReportsAntineoplastic AgentsAreaArtificial nanoparticlesBindingBiotechnologyBlood CirculationBotanicalsBusinessesCancer CenterCancer PatientCancer Patient Education NetworkCaringClinicClinicalClinical TrialsCollaborationsColorectalCommerceCommunitiesCommunity Health EducationCommunity HospitalsCommunity PhysicianComputersCountyDevelopmentDiagnosisDiscipline of NursingDiseaseDoctor of MedicineEducationEducational ActivitiesEducational workshopElectronic MailElectronicsEnsureEnvironmentEventFaceFacultyFamilyFoundationsGoalsGovernmentGroup MeetingsGrowthGuidelinesHealthHealth ProfessionalHealth systemHealthcareHospitalsHouseholdIllinoisImageIndustryInformation CentersInformation ResourcesInformation ServicesInstitutionInternetJournalsLibrariesLinkLiteratureLobbyingMailsMalignant NeoplasmsMedicineMissouriNamesNanotechnologyNew AgentsNewsletterNewspapersNursesOncologistPaclitaxelPamphletsPatientsPharmaceutical PreparationsPharmacologic SubstancePhysiciansPlantsPreventionPrevention programProteinsProviderPublicationsPublishingRaceRadioReadingReportingResearchResearch PersonnelResourcesRoleRouteSamplingScienceScreening for cancerScreening procedureServicesSiteSurgeonTechnologyTelevisionTreatment EffectivenessUniversitiesUpdateWashingtonWomanWorkWritingbasecancer carecancer diagnosiscancer educationcancer riskcancer therapycommunity organizationscontinuing medical educationdesignfollower of religion Jewishimprovedinterestlecturesmalignant breast neoplasmmedical schoolsmeetingsmembermetermetropolitannanomedicinenanoparticlenanoscalenanosciencenanosizednoveloncologyprogramsscientific organizationsquare footsymposiumtooltumorweb pageweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CORE C4: Education and Dissemination of Nanomedicine in Cancer (EDNIC)
Introduction
Nanotechnology, the work which takes place with clusters of atoms and molecules approximately the size
of a billionth of a meter, is emerging in the marketplace and will impact all aspects of industry, changing the
face of materials, energy, electronics, and healthcare.1 Nanoscale imaging agents will allow clinicians to
detect disease early and assess effectiveness of treatment. Importantly, "nano-sized" drugs may customize
the treatment of all diseases. The FDA recently approved an existing anticancer agent, paclitaxel, bound to a
protein nanoparticle for use in patients with metastatic breast cancer. This new agent, paclitaxel, nanoparticle,
albumin-bound (Abraxane¿, American Pharmaceutical Partners, Inc. and American Bioscience, Inc.) was
approved on January 7, 2005.2 This recent approval marks the beginning of the use of nanotechnology in
healthcare, and importantly, in the field of cancer.
Despite the promise of dramatic breakthroughs in the field of medicine and, in particular, in the diagnosis
and treatment of cancer, the field of nanoscience must overcome two key challenges. First and foremost,
researchers must demonstrate to the community that engineered nanoparticles used for the diagnosis or
treatment of cancer are safe and will not harm the body or the environment. Second, researchers must ensure
that the hype around the potential uses of this technology in cancer will not backfire if fewer than expected
uses are successful. Therefore, it is imperative that both healthcare professionals and the community are well
educated about the potential uses of nanotechnology in the diagnosis and treatment of cancer.
The St. Louis metro area, which encompasses 12 counties in the Missouri and Illinois bi-state area, brings
unique opportunities to the field of nanomedicine. The Education and Dissemination of Nanomedicine in
Cancer Core (EDNIC) of the SCCNE will utilize many of the educational and informational programs set up by
the SCC for this purpose. In doing so, the EDNIC Core will not only provide a basic understanding of
nanotechnology in cancer but also inform our community of the work being done at the SCCNE and throughout
the world.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)
-
批准号:7738085
-
项目类别:
-
资助金额:$6.7万
-
财政年份:2008
-
负责人:PAULA M. FRACASSO
-
依托单位:
An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast
-
批准号:7275903
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2007
-
负责人:PAULA M. FRACASSO
-
依托单位:
An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast
-
批准号:7498461
-
项目类别:
-
资助金额:$26.92万
-
财政年份:2007
-
负责人:PAULA M. FRACASSO
-
依托单位:
Overcoming Barriers to Early Phase Clinical Trials
-
批准号:6666028
-
项目类别:
-
资助金额:$12.48万
-
财政年份:2003
-
负责人:PAULA M. FRACASSO
-
依托单位:
Overcoming Barriers to Early Phase Clinical Trials
-
批准号:6784071
-
项目类别:
-
资助金额:$20.66万
-
财政年份:2003
-
负责人:PAULA M. FRACASSO
-
依托单位:
Overcoming Barriers to Early Phase Clinical Trials
-
批准号:6879368
-
项目类别:
-
资助金额:$7.66万
-
财政年份:2003
-
负责人:PAULA M. FRACASSO
-
依托单位:
TAXOL AND SDZ PSC 833 IN PATIENTS WITH REFRACTORY MALIGNANCIES
-
批准号:6274210
-
项目类别:
-
资助金额:$2.24万
-
财政年份:1997
-
负责人:PAULA M. FRACASSO
-
依托单位:
TAXOL AND SDZ PSC 833 IN PATIENTS WITH REFRACTORY MALIGNANCIES
-
批准号:6244194
-
项目类别:
-
资助金额:$2.25万
-
财政年份:1997
-
负责人:PAULA M. FRACASSO
-
依托单位:
ORAL SDZ PSC 833 AND INTRAVENOUS PACLITAXEL IN ADVANCED CANCER
-
批准号:6274237
-
项目类别:
-
资助金额:$2.24万
-
财政年份:1997
-
负责人:PAULA M. FRACASSO
-
依托单位:
COMPARISON OF CDNA TRANSCRIPTS OF MDR GENES IN THE MOUSE
-
批准号:3033761
-
项目类别:
-
资助金额:$0.71万
-
财政年份:1991
-
负责人:PAULA M. FRACASSO
-
依托单位:
COMPARISON OF CDNA TRANSCRIPTS OF MDR GENES IN THE MOUSE
-
批准号:3033762
-
项目类别:
-
资助金额:$3.3万
-
财政年份:1990
-
负责人:PAULA M. FRACASSO
-
依托单位:
COMPARISON OF CDNA TRANSCRIPTS OF MDR GENES IN THE MOUSE
-
批准号:3033760
-
项目类别:
-
资助金额:$2.7万
-
财政年份:1988
-
负责人:PAULA M. FRACASSO
-
依托单位:
ORAL SDZ PSC 833 AND INTRAVENOUS PACLITAXEL IN ADVANCE CANCER
-
批准号:5215805
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PAULA M. FRACASSO
-
依托单位:--
TAXOL AND SDZ PSC 833 IN PATIENTS WITH REFRACTORY MALIGNANCIES
-
批准号:6112976
-
项目类别:
-
资助金额:$2.34万
-
财政年份:--
-
负责人:PAULA M. FRACASSO
-
依托单位:
ORAL SDZ PSC 833 AND INTRAVENOUS PACLITAXEL IN ADVANCED CANCER
-
批准号:6113003
-
项目类别:
-
资助金额:$2.34万
-
财政年份:--
-
负责人:PAULA M. FRACASSO
-
依托单位:
海外基金